Skip to main content
. Author manuscript; available in PMC: 2015 Jul 20.
Published in final edited form as: J Allergy Clin Immunol. 2009 Dec;124(6):1129–1140. doi: 10.1016/j.jaci.2009.11.001

TABLE II.

FDA-approved IL-1–targeted therapies

Compound Structure Target Half-life Dosing frequency Other features
Anakinra (Kineret) Recombinant IL-1 receptor antagonist IL-1 receptor 4–6 h Daily Common painful injection-site reactions
Rilonacept (Arcalyst) Fusion protein, including IL-1 receptor and IL-1 receptor accessory protein (IL-1 TRAP) IL-1β (also IL-1α and IL-1Ra) 8.6 d Weekly Minor injection-site reactions
Canakinumab (Ilaris) Humanized mAb to IL-1β IL-1β 28 d 2 mo Minimal injection-site reactions